company background image
LMAT

LeMaitre VascularNasdaqGM:LMAT Stock Report

Market Cap

US$1.2b

7D

0.2%

1Y

65.8%

Updated

16 Oct, 2021

Data

Company Financials +
LMAT fundamental analysis
Snowflake Score
Valuation2/6
Future Growth1/6
Past Performance5/6
Financial Health5/6
Dividends3/6

LMAT Overview

LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide.

LeMaitre Vascular Competitors

Price History & Performance

Summary of all time highs, changes and price drops for LeMaitre Vascular
Historical stock prices
Current Share PriceUS$53.58
52 Week HighUS$31.21
52 Week LowUS$64.50
Beta1.33
1 Month Change-7.86%
3 Month Change-2.60%
1 Year Change65.83%
3 Year Change91.02%
5 Year Change169.65%
Change since IPO764.19%

Recent News & Updates

Sep 08
With EPS Growth And More, LeMaitre Vascular (NASDAQ:LMAT) Is Interesting

With EPS Growth And More, LeMaitre Vascular (NASDAQ:LMAT) Is Interesting

It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...

Aug 07
Is It Too Late To Consider Buying LeMaitre Vascular, Inc. (NASDAQ:LMAT)?

Is It Too Late To Consider Buying LeMaitre Vascular, Inc. (NASDAQ:LMAT)?

LeMaitre Vascular, Inc. ( NASDAQ:LMAT ), is not the largest company out there, but it led the NASDAQGM gainers with a...

Jul 04
We Think LeMaitre Vascular (NASDAQ:LMAT) Can Manage Its Debt With Ease

We Think LeMaitre Vascular (NASDAQ:LMAT) Can Manage Its Debt With Ease

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Shareholder Returns

LMATUS Medical EquipmentUS Market
7D0.2%0.6%2.0%
1Y65.8%20.0%27.6%

Return vs Industry: LMAT exceeded the US Medical Equipment industry which returned 20% over the past year.

Return vs Market: LMAT exceeded the US Market which returned 27.6% over the past year.

Price Volatility

Is LMAT's price volatile compared to industry and market?
LMAT volatility
LMAT Beta1.33
Industry Beta0.88
Market Beta1

Stable Share Price: LMAT is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: LMAT's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1983395George LeMaitrehttps://www.lemaitre.com

LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. It offers angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system. The company also provides carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; powered phlebectomy devices to remove varicose veins; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient’s body, and allows them to locate tributaries or lesions beneath the skin.

LeMaitre Vascular Fundamentals Summary

How do LeMaitre Vascular's earnings and revenue compare to its market cap?
LMAT fundamental statistics
Market CapUS$1.17b
Earnings (TTM)US$28.77m
Revenue (TTM)US$150.52m

40.6x

P/E Ratio

7.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
LMAT income statement (TTM)
RevenueUS$150.52m
Cost of RevenueUS$52.85m
Gross ProfitUS$97.67m
ExpensesUS$68.89m
EarningsUS$28.77m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

Oct 28, 2021

Earnings per share (EPS)1.32
Gross Margin64.89%
Net Profit Margin19.12%
Debt/Equity Ratio12.1%

How did LMAT perform over the long term?

See historical performance and comparison

Dividends

0.8%

Current Dividend Yield

29%

Payout Ratio

Valuation

Is LeMaitre Vascular undervalued compared to its fair value and its price relative to the market?

10.5%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: LMAT ($53.58) is trading below our estimate of fair value ($59.87)

Significantly Below Fair Value: LMAT is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: LMAT is good value based on its PE Ratio (40.6x) compared to the US Medical Equipment industry average (48.4x).

PE vs Market: LMAT is poor value based on its PE Ratio (40.6x) compared to the US market (18.2x).


Price to Earnings Growth Ratio

PEG Ratio: LMAT is poor value based on its PEG Ratio (3.7x)


Price to Book Ratio

PB vs Industry: LMAT is overvalued based on its PB Ratio (6.3x) compared to the US Medical Equipment industry average (4.3x).


Future Growth

How is LeMaitre Vascular forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

11.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: LMAT's forecast earnings growth (11% per year) is above the savings rate (2%).

Earnings vs Market: LMAT's earnings (11% per year) are forecast to grow slower than the US market (15.1% per year).

High Growth Earnings: LMAT's earnings are forecast to grow, but not significantly.

Revenue vs Market: LMAT's revenue (6.6% per year) is forecast to grow slower than the US market (9.9% per year).

High Growth Revenue: LMAT's revenue (6.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: LMAT's Return on Equity is forecast to be low in 3 years time (12.6%).


Past Performance

How has LeMaitre Vascular performed over the past 5 years?

13.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: LMAT has high quality earnings.

Growing Profit Margin: LMAT's current net profit margins (19.1%) are higher than last year (14.4%).


Past Earnings Growth Analysis

Earnings Trend: LMAT's earnings have grown by 13.9% per year over the past 5 years.

Accelerating Growth: LMAT's earnings growth over the past year (74.7%) exceeds its 5-year average (13.9% per year).

Earnings vs Industry: LMAT earnings growth over the past year (74.7%) exceeded the Medical Equipment industry 36.1%.


Return on Equity

High ROE: LMAT's Return on Equity (15.5%) is considered low.


Financial Health

How is LeMaitre Vascular's financial position?


Financial Position Analysis

Short Term Liabilities: LMAT's short term assets ($90.0M) exceed its short term liabilities ($21.5M).

Long Term Liabilities: LMAT's short term assets ($90.0M) exceed its long term liabilities ($39.2M).


Debt to Equity History and Analysis

Debt Level: LMAT's debt to equity ratio (12.1%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if LMAT's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: LMAT's debt is well covered by operating cash flow (197.1%).

Interest Coverage: LMAT's interest payments on its debt are well covered by EBIT (16.9x coverage).


Balance Sheet


Dividend

What is LeMaitre Vascular current dividend yield, its reliability and sustainability?

0.82%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: LMAT's dividend (0.82%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.29%).

High Dividend: LMAT's dividend (0.82%) is low compared to the top 25% of dividend payers in the US market (3.49%).


Stability and Growth of Payments

Stable Dividend: LMAT's dividends per share have been stable in the past 10 years.

Growing Dividend: LMAT's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (29.1%), LMAT's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

14.3yrs

Average management tenure


CEO

George LeMaitre (56 yo)

29.33yrs

Tenure

US$1,386,506

Compensation

Mr. George W. LeMaitre has been Chief Executive Officer of Lemaitre Vascular, Inc. since June 1992 and has been its Chairman since 2004. Mr. LeMaitre served as the President of Lemaitre Vascular from June...


CEO Compensation Analysis

Compensation vs Market: George's total compensation ($USD1.39M) is below average for companies of similar size in the US market ($USD2.26M).

Compensation vs Earnings: George's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: LMAT's management team is seasoned and experienced (14.3 years average tenure).


Board Members

Experienced Board: LMAT's board of directors are seasoned and experienced ( 17.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7.8%.


Top Shareholders

Company Information

LeMaitre Vascular, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: LeMaitre Vascular, Inc.
  • Ticker: LMAT
  • Exchange: NasdaqGM
  • Founded: 1983
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$1.169b
  • Shares outstanding: 21.81m
  • Website: https://www.lemaitre.com

Number of Employees


Location

  • LeMaitre Vascular, Inc.
  • 63 Second Avenue
  • Burlington
  • Massachusetts
  • 1803
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/16 22:19
End of Day Share Price2021/10/15 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.